Monitor future equity grant disclosures to gauge actual dilution. The CEO transition is fully resolved; no near-term operational catalysts from this filing.
Price Chart
Executive Summary
Integra LifeSciences reported results from its 2026 Annual Meeting. Stockholders approved a 3,550,000-share increase to the equity incentive plan and elected all seven director nominees. The filing is procedural and follows the previously disclosed CEO transition.
Key Facts
- Stockholders approved Amendment No. 3 to the 2003 Equity Incentive Plan, increasing shares available by 3,550,000 to a total of 24,250,000.
- All seven director nominees were elected, including Stuart Essig as Chairman and CEO.
- Say-on-pay proposal and ratification of PricewaterhouseCoopers as auditor were also approved.
- Former CEO Mojdeh Poul did not stand for election as previously disclosed in the DEFA14A filed May 5, 2026.
Financial Impact
The equity plan share increase of 3,550,000 represents potential dilution of approximately 3.5% of current outstanding shares, but no immediate dilution as shares are authorized, not issued.
Risk Factors
- Potential future dilution from equity awards granted under the expanded plan.
- Continued low analyst bullish sentiment (13% buy) suggests limited near-term upside.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000917520-26-000044 |
| Exhibit: ex101_amendequityplanxapri.htm | 0000917520-26-000044 |
| Document: 0000917520-26-000044-index-headers.html | 0000917520-26-000044 |
| Document: 0000917520-26-000044-index.html | 0000917520-26-000044 |
| Document: 0000917520-26-000044.txt | 0000917520-26-000044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $11.84 | awaiting T+5 | — | $12.12 (−2.36%) |
Oct 19, 2026 6d ago | 8-K | $13.33 | awaiting T+5 | — | $12.12 (−9.08%) |
Oct 14, 2026 12d ago | Court Ruling | $13.53 $12.33 | ▼ −8.91% | ▼ −7.89% | $12.12 (−10.42%) |
Oct 13, 2026 12d ago | 3 | $13.18 $11.84 | ▼ −10.13% | ▼ −10.59% | $12.12 (−8.01%) |
Oct 9, 2026 16d ago | 8-K | $13.98 $13.45 | ▲ +3.79% | ▲ +2.30% | $12.12 (+13.30%) |
Oct 6, 2026 20d ago | Press Release | $13.32 | awaiting T+5 | — | $12.12 (−9.01%) |
Oct 2, 2026 24d ago | 8-K | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.12 (+4.42%) |
Oct 2, 2026 24d ago | Press Release | $12.68 $13.44 | ▼ −5.99% | ▼ −4.83% | $12.12 (+4.42%) |
Sep 8, 2026 6w ago | 8-K | $16.26 $15.71 | ▼ −3.38% | ▼ −2.72% | $12.12 (−25.46%) |
May 8, 2026 24w ago | 8-K | $13.97 $14.11 | ▲ +1.00% | ▲ +1.09% | $12.12 (−13.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers